Compare Marathon Digital Holdings Inc (MARA) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance

Marathon Digital Holdings IncTrade

Recursion Pharmaceuticals IncTrade

Price performance (Past 24H)

Key statistics

Marathon Digital Holdings Inc vs Recursion Pharmaceuticals Inc — how do they compare? Marathon Digital Holdings Inc trades at $9.9 (market cap $3.74B), while Recursion Pharmaceuticals Inc trades at $3.35 (market cap $1.81B). The key difference: Marathon Digital Holdings Inc is far larger — about 2.1× Recursion Pharmaceuticals Inc's market cap. Which is the better fit depends on your goals.

	MARA	RXRX
Market Cap	$3.74B	$1.81B
Sector	Technology	Health
52-Week High	$22.84	$6.79
52-Week Low	$6.73	$2.84
Enterprise Value	$5.78B	$1.33B

View details →View details →

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

MARA

MicroStrategy stock down 75% but analysts see 139% upside on bitcoin rebound hopes24/7 Wall Street · 1 day agoNeutral Bitcoin miners' stocks drop 5-6% amid Strategy's Bitcoin and stock sales, weighing on crypto sentiment.24/7 Wall Street · 1 day agoBearish View details →

RXRX

Recursion Pharmaceuticals faces slow growth and cash burn despite AI drug discovery partnerships.Seeking Alpha · 1 day agoBearish View details →

About Marathon Digital Holdings Inc

Marathon Digital Holdings, Inc. is one of the largest publicly traded Bitcoin mining companies in North America. The company focuses on building and operating large-scale, cost-efficient Bitcoin mining facilities. Marathon's strategy centers on increasing its mining hash rate and using sustainable energy sources to expand its Bitcoin production. The company's performance is closely tied to the price of Bitcoin and the overall health of the digital asset mining industry.

About Recursion Pharmaceuticals Inc

Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.